{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:31:14Z","timestamp":1785450674191,"version":"3.56.0"},"reference-count":29,"publisher":"Jaypee Brothers Medical Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.59556\/japi.73.0938","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:21:23Z","timestamp":1751001683000},"page":"e15-e22","source":"Crossref","is-referenced-by-count":4,"title":["Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context"],"prefix":"10.59556","volume":"73","author":[{"given":"Krishna G","family":"Seshadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash K","family":"Wangnoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Sosale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Kumar","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadra","family":"Polisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi Krishna","family":"Kolukula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(7):","key":"key20250627052118_B1","doi-asserted-by":"crossref","first-page":"474-","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20250627052118_B2","doi-asserted-by":"crossref","first-page":"S140\u2212","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in diabetes\u20142023.","volume":"46:","author":"ElSayed","year":"2023;","journal-title":"Diabetes Care"},{"key":"key20250627052118_B3","doi-asserted-by":"crossref","first-page":"1-","DOI":"10.1007\/s13410-020-00819-2","article-title":"RSSDI\u2212ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020.","volume":"24:","author":"Chawla","year":"2020;","journal-title":"Int J Diabetes Dev Ctries"},{"key":"key20250627052118_B4","doi-asserted-by":"crossref","first-page":"852-","DOI":"10.1111\/j.1463-1326.2012.01611.x","article-title":"Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.","volume":"14:","author":"Pirags","year":"2012;","journal-title":"Diabetes Obes Metab"},{"issue":"(4):","key":"key20250627052118_B5","doi-asserted-by":"crossref","first-page":"952\u2212","DOI":"10.2337\/dc20-0763","article-title":"Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial.","volume":"44","author":"Dubourg","year":"2021;","journal-title":"Diabetes Care"},{"issue":"(2):","key":"key20250627052118_B6","doi-asserted-by":"crossref","first-page":"102710.","DOI":"10.1016\/j.dsx.2023.102710","article-title":"Efficacy and safety of imeglimin in type 2 diabetes: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"17","author":"Singh","year":"2023;","journal-title":"Diabetes Metab Syndr"},{"key":"key20250627052118_B7","unstructured":"Approval of imeglimin in Japan. Pharmaceutical evaluation division. Pharmaceutical Safety and Environmental Health Bureau Ministry of Health. Approval of imeglimin in Japan. Pharmaceutical evaluation division. Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare. Japan, https:\/\/www.pmda.go.jp\/files\/000246722.pdf."},{"key":"key20250627052118_B8","unstructured":"Approval of imeglimin in India. Weblink: https:\/\/www.cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCTApprovals\/94%20Exemed%20Imeglimin%20CT\u221206.pdf"},{"issue":"(3):","key":"key20250627052118_B9","doi-asserted-by":"crossref","first-page":"664\u2212","DOI":"10.1111\/dom.14277","article-title":"Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes.","volume":"23","author":"Hallakou-Bozec","year":"2021;","journal-title":"Diabetes Obes Metab"},{"issue":"(3):","key":"key20250627052118_B10","doi-asserted-by":"crossref","first-page":"227\u2212","DOI":"10.1007\/s40268-015-0099-3","article-title":"Imeglimin: a potential new multi-target drug for type 2 diabetes.","volume":"15","author":"Vuylsteke","year":"2015;","journal-title":"Drugs R D"},{"key":"key20250627052118_B11","doi-asserted-by":"crossref","first-page":"2254-","DOI":"10.2337\/db14-1220","article-title":"Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.","volume":"64:","author":"Vial","year":"2015;","journal-title":"Diabetes"},{"key":"key20250627052118_B12","doi-asserted-by":"crossref","first-page":"1330-","DOI":"10.1124\/dmd.120.000154","article-title":"In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans.","volume":"48:","author":"Chevalier","year":"2020;","journal-title":"Drug Metab Dispos"},{"key":"key20250627052118_B13","doi-asserted-by":"crossref","first-page":"565-","DOI":"10.2337\/dc12-0453","article-title":"The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.","volume":"36:","author":"Fouqueray","year":"2013;","journal-title":"Diabetes Care"},{"key":"key20250627052118_B14","doi-asserted-by":"crossref","first-page":"1924-","DOI":"10.2337\/dc13-2349","article-title":"The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.","volume":"37:","author":"Fouqueray","year":"2014;","journal-title":"Diabetes Care"},{"key":"key20250627052118_B15","article-title":"Dose-ranging study to determine the optimum dose for imeglimin, a novel treatment for type 2 diabetes.","volume-title":"75th Scientific Sessions of the American Diabetes Association,","author":"Fouqueray","year":"2015."},{"key":"key20250627052118_B16","doi-asserted-by":"crossref","first-page":"800-","DOI":"10.1111\/dom.14285","article-title":"Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.","volume":"23:","author":"Dubourg","year":"2021;","journal-title":"Diabetes Obes Metab"},{"issue":"(6):","key":"key20250627052118_B17","doi-asserted-by":"crossref","first-page":"e371.","DOI":"10.1002\/edm2.371","article-title":"Phase 2 trial with imeglimin in patients with type 2 diabetes indicates effects on insulin secretion and sensitivity.","volume":"5","author":"Theurey","year":"2022;","journal-title":"Endocrinol Diabetes Metab"},{"issue":"(4):","key":"key20250627052118_B18","doi-asserted-by":"crossref","first-page":"609\u2212","DOI":"10.1111\/dom.14613","article-title":"Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial.","volume":"24","author":"Dubourg","year":"2022;","journal-title":"Diabetes Obes Metab"},{"issue":"(5):","key":"key20250627052118_B19","doi-asserted-by":"crossref","first-page":"838\u2212","DOI":"10.1111\/dom.14642","article-title":"Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.","volume":"24","author":"Reilhac","year":"2022;","journal-title":"Diabetes Obes Metab"},{"issue":"(3):","key":"key20250627052118_B20","doi-asserted-by":"crossref","first-page":"569\u2212","DOI":"10.1007\/s13300-023-01370-z","article-title":"Improving the effects of imeglimin on endothelial function: a prospective, single-center, observational study.","volume":"14","author":"Uchida","year":"2023;","journal-title":"Diabetes Ther"},{"issue":"(9):","key":"key20250627052118_B21","doi-asserted-by":"crossref","first-page":"1635\u2212","DOI":"10.1007\/s13300-022-01298-w","article-title":"The effects of imeglimin on the daily glycemic profile evaluated by intermittently scanned continuous glucose monitoring: retrospective, single-center, observational study.","volume":"13","author":"Oda","year":"2022;","journal-title":"Diabetes Ther"},{"issue":"(3):","key":"key20250627052118_B22","doi-asserted-by":"crossref","first-page":"1334\u2212","DOI":"10.21873\/invivo.13214","article-title":"Safety and efficacy of imeglimin for type 2 diabetes in patients undergoing dialysis.","volume":"37","author":"Mima","year":"2023;","journal-title":"In Vivo"},{"issue":"(3):","key":"key20250627052118_B23","doi-asserted-by":"crossref","first-page":"458-","DOI":"10.1287\/mnsc.9.3.458","article-title":"An experimental application of the Delphi method to the use of experts.","volume":"9","author":"Dalkey","year":"1963;","journal-title":"Manag Sci"},{"key":"key20250627052118_B24","doi-asserted-by":"crossref","first-page":"376-","DOI":"10.1046\/j.1365-2648.2003.02537.x","article-title":"The Delphi technique: myths and realities.","volume":"41:","author":"Powell","year":"2003;","journal-title":"J Adv Nurs"},{"issue":"(6):","key":"key20250627052118_B25","doi-asserted-by":"crossref","first-page":"541-","DOI":"10.1111\/dom.12452","article-title":"Imeglimin increases glucose-dependent insulin secretion and improves \u03b2-cell function in patients with type 2 diabetes.","volume":"17","author":"Pacini","year":"2015;","journal-title":"Diabetes Obes Metab"},{"issue":"(4):","key":"key20250627052118_B26","doi-asserted-by":"crossref","first-page":"1014\u2212","DOI":"10.1111\/cts.13221","article-title":"Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.","volume":"15","author":"Tomita","year":"2022;","journal-title":"Clin Transl Sci"},{"issue":"(8):","key":"key20250627052118_B27","first-page":"871\u2212","article-title":"Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy.","volume":"21","author":"Johansson","year":"2020;"},{"key":"key20250627052118_B28","doi-asserted-by":"crossref","first-page":"1261\u2212","DOI":"10.1007\/s40262-020-00886-y","article-title":"Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects.","volume":"59:","author":"Fouqueray","year":"2020;","journal-title":"Clin Pharmacokinet"},{"issue":"(2):","key":"key20250627052118_B29","doi-asserted-by":"crossref","first-page":"361\u2212","DOI":"10.5603\/EP.a2022.0014","article-title":"Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.","volume":"73","author":"Nowak","year":"2022;","journal-title":"Endokrynol Pol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:21:27Z","timestamp":1751001687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-73-6-e15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.59556\/japi.73.0938"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.0938","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}